Researchers explore function of cancer-causing gene

March 26, 2014

Developmental biologists at the University of Georgia are discovering new roles for a specific gene known as Max's Giant Associated protein, or MGA. A little studied protein, MGA appears to control a number of developmental processes, and also may be connected to cancer development.

The researchers detail their findings in a paper published recently in the journal Developmental Cell.

"The same genes that are involved in building a person during can mutate and cause cancer later in life," said Scott Dougan the study's principal investigator and Georgia Cancer Coalition Distinguished Cancer Scientist in UGA's Department of Cellular Biology. "No one has done a systematic study of MGA, but now that some studies connect it to cancer, there is tremendous interest."

The most common cancer associated with MGA is chronic lymphocytic leukemia, a blood and in which the body produces too many . Preliminary tests suggest that this might develop when MGA does not successfully control the activities of another protein known as MYC, which contributes to tumor growth.

Dougan and his team of researchers used their own methods to change the levels of MGA in the embryos of zebrafish to see if they could discover any other roles for MGA.

They found that MGA also helps control expression of the Bone Morphogenetic Proteins, or BMP, which, as the name implies, are responsible for bone development in the embryo. In adults, however, changes in BMP activity can result in tumor development, and MGA may be part of this detrimental transformation.

"Scientists are only beginning to understand the roles this MGA protein plays, but our tests show that MGA may control many more processes than first imagined," said Dougan, who is also a member of UGA's Developmental Biology Alliance. "MGA may be involved in a number of other cancers, but we need to do more research before we're sure."

In the coming months, Dougan and his research team plan to further examine the roles of MGA to determine when it controls MYC, when it controls BMP and how it is involved in tumor formation.

"This is basic science, and we need investigations like these to understand the fundamentals of our biology," Dougan said. "Once we have this understanding, we can begin to develop new therapies to treat diseases in new, more effective ways."

Explore further: New findings on neurogenesis in the spinal cord

More information: http://www.cell.com/developmental-cell/abstract/S1534-5807(14)00026-4

Related Stories

New findings on neurogenesis in the spinal cord

March 5, 2014
Research from Karolinska Institutet in Sweden suggests that the expression of the so called MYC gene is important and necessary for neurogenesis in the spinal cord. The findings are being published in the journal EMBO Reports.

Zebra fish fins help researchers gain insight into bone regeneration

January 30, 2014
University of Oregon biologists say they have opened the window on the natural process of bone regeneration in zebra fish, and that the insights they gained could be used to advance therapies for bone fractures and disease.

Researchers discover a tumor suppressor gene in a very aggressive lung cancer

January 9, 2014
The Genes and Cancer Group at the Cancer Epigenetics and Biology Program of the IDIBELL has found that the MAX gene, which encodes a partner of the MYC oncogene, is genetically inactivated in small cell lung cancer. Reconstitution ...

Regulator of gene expression responsible for the progression of breast cancer

February 28, 2014
Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

Tumor-suppressing genes could play important role in obesity, diabetes and cancer

December 11, 2013
The function of two tumor-suppressing genes could play a vital role in helping to control obesity and other diseases such as diabetes, heart disease and cancer, according to researchers in Temple University's Sbarro Institute ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.